ArticleJournal of neuro-oncology2012
Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.
Article in Journal of neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.Journal of neuro-oncology · 2020Pooled it
- Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.Neuro-oncology · 2016Pooled it
- Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial.European journal of nutrition · 2022Trial
- Imaging in Neuro-oncology.Seminars in neurology · 2025Review
- Improving the Quality of Brain PET Images Using MR-Guided PET Reconstruction Technique With Integrated PET/MR.Human brain mapping · 2025Article
- Review
- Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.Neuro-oncology · 2021Article
- Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[Radiation oncology (London, England) · 2019Article
- Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma.Frontiers in oncology · 2019Review
- Prognostic Value of MTV, SUVmax and the T/N Ratio of PET/CT in Patients with Glioma: A Systematic Review and Meta-Analysis.Journal of Cancer · 2019Article
- Radiomics in Oncological PET/CT: Clinical Applications.Nuclear medicine and molecular imaging · 2018Review
- IDH mutation is paradoxically associated with higherEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.European journal of nuclear medicine and molecular imaging · 2017Article
- Non-invasive metabolic imaging of brain tumours in the era of precision medicine.Nature reviews. Clinical oncology · 2016Review
- Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Neuro-oncology · 2016Review
- Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma.Journal of medical radiation sciences · 2014Article
- 18 F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma.EJNMMI research · 2014Article
- GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.Journal of neuro-oncology · 2013Article
- Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis.European journal of nuclear medicine and molecular imaging · 2013Review
- FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.Neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic value of PET with (18F)-fluoro-2-deoxy-D: -glucose (FDG) has been shown in high-grade gliomas (HGG), but not compared with consensual prognostic factors. We sought to evaluate the independent predictive value of pre-treatment FDG-PET on overall (OS) and event-free survival (EFS). We retrospectively analyzed 41 patients with histologically-confirmed HGG (31 glioblastomas and 10 anaplastic gliomas). The pre-treatment uptake of FDG was assessed qualitatively by five-step visual metabolic grading, and quantitatively by the ratio between the tumor and contralateral maximal standardized uptake value (T/CL). EFS and OS following PET were compared with FDG uptake by univariate analysis, and by two multivariate analyses: one including main consensual prognostic factors (age, KPS, extent of surgery and histological grade), and the other including the classification system of the Radiation Therapy Oncology Group (Recursive Partitioning Analysis, RPA). Median OS and EFS were 13.8 and 7.4 months, respectively, for glioblastomas, and over 25.8 and 12 months, respectively, for anaplastic gliomas (P = 0.040 and P = 0.027). The T/CL ratio predicted OS in the entire group [P = 0.003; Hazard Ratio (HR) = 2.3] and in the glioblastoma subgroup (P = 0.018; HR = 2), independently of age, Karnofsky performance status, histological grade, and surgery, and independently of RPA classification. T/CL ratio tended to predict EFS in the whole group (P = 0.052). The prognostic value of visual metabolic grade on OS was less significant than T/CL ratio, both in the entire group and in the glioblastoma subgroup (P = 0.077 and P = 0.059). Quantitative evaluation of the ratio between the maximal tumor and contralateral uptake in pre-treatment FDG-PET provides significant additional prognostic information in newly-diagnosed HGG, independently of consensual prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.